Tag Archives: tirzepatide
Tirzepatide in Prader-Willi: 3 Measures After One Swap
Tirzepatide replaced a GLP-1 agonist in a woman with Prader-Willi syndrome and refractory diabetes, and appetite, weight and glucose all improved.
Tirzepatide and Metformin: When Glucose Masks Ketoacidosis
Tirzepatide with metformin preceded severe lactic acidosis and ketoacidosis at near-normal glucose in a 59-year-old woman, who recovered on dialysis.
Tirzepatide Regain: 1.04 kg a Month, 15 Months Modelled
Tirzepatide and semaglutide users regained 1.04 kg a month after stopping. The 15 months to baseline is an extrapolation, not an observation.
Retatrutide at 22.1%: What the Table Does Not Show
Retatrutide reached 22.1% placebo-subtracted weight loss in an Annals review of 38 trials, where heterogeneity blocked quantitative synthesis.
Tirzepatide CV Approval: The Overlooked 0.92 Hazard Ratio
Tirzepatide gained an FDA cardiovascular indication on 28 August 2026, from a trial that met non-inferiority and missed superiority at P = 0.09.
GLP-1 in Serious Mental Illness: 764,115 Matched Pairs
GLP-1 initiation was linked to lower four-year mortality than SGLT2 inhibitors in serious mental illness, and the absolute gap was larger there.
GLP-1 Below BMI 27: Benefit With Little Weight to Lose
GLP-1 receptor agonists cut coded heart failure in type 2 diabetes with a BMI under 27, where there is almost no weight left to lose.
Semaglutide vs Tirzepatide in FAERS: 192,791 US Reports
Semaglutide carried the cardiac reporting signals in a 2026 FAERS analysis, despite tirzepatide having more than twice as many reports overall.
Retatrutide Led 3 GLP-1 Drugs on Kidney Fibrosis in Mice
Retatrutide, tirzepatide and semaglutide were run through the same two mouse models of kidney scarring. Each engaged a different pathway.
Tirzepatide Plus TOFA: More Than Additive in Obese Mice
Tirzepatide works by cutting food intake. A 2026 Science Advances paper reports an oral molecule that cuts fat without touching intake, and adds to it.